Sanofi’s Kevzara recommended by NICE for rheumatoid arthritis

Sanofi has announced that its rheumatoid arthritis drug Kevzara has been recommended for approval by the National Institute for Health and Care Excellence (NICE).

A final appraisal determination from the regulator has endorsed Kevzara for routine use on the NHS in England in combination with methotrexate as a treatment option for adults with severe, active rheumatoid arthritis who have responded inadequately to prior therapy.

The drug was also recommended as a monotherapy in adults with severe, active rheumatoid arthritis who are intolerant to methotrexate. Final NICE guidance for Kevzara is expected to follow these draft recommendations later this year.

More than 400,000 people in the UK live with rheumatoid arthritis, and it is hoped that this drug can represent a promising new therapeutic option for these patients.

Peter Kuiper, general manager for the UK and Ireland at Sanofi Genzyme, said: "This recommendation brings us one step closer to making Kevzara available to adult patients with severe rheumatoid arthritis."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.